Imaging Diagnostics and Therapeutics Program

成像、诊断和治疗计划(IDT)是一个新的人机界面计划，专注于翻译 癌症生物学的基本发现与临床相关的先进成像技术、诊断、药物 给药系统、独特的治疗方法和临床试验。IDT的一个主要目标是利用 犹他大学在遗传学、制药学、成像以及基础设施方面的优势 使个性化肿瘤学成为现实的资源。IDT的一个优先事项是增加与 多学科疾病小组，以更好地了解未满足的临床需求，并带来理论和 从临床前项目到人类应用。IDT是按照它的三个主题科学优势组织的： 成像研究的努力包括技术开发、图像引导治疗以及新的和不断发展的 分子成像学科。几个计划成员专注于使用正电子发射 用独特的放射性药物进行断层成像以评估对治疗干预的早期反应。 一些成员还参与了图像引导治疗技术的开发。 诊断学研究工作包括开发新的诊断策略以改善生物 为癌症的治疗提供重要的预后信息 改善癌症护理。该计划中的几个人对使用现代分子感兴趣 评估哪些人群有患某种癌症的风险以及如何发生癌症的技术 某些癌症对靶向药物治疗有反应。此外，有关肿瘤的预后信息 行为是可以评估的。从诊断生物标记物开发的这些努力中，分子缺陷 可以识别路径或目标。 治疗学研究工作包括开发使用新药和药物的治疗策略 传输系统。这些IDT成员执行临床前开发、药理学和其他所需的 将他们的发现转化为临床应用的研究。会员追求新药和诊断方法 通过设计、化合物筛选、计算建模和化学合成。成员还专注于 利用新型大分子药物和药物向肿瘤和转移靶向输送抗癌药物 新的控释和亲药物技术。这一专题小组对HCI的临床试验工作至关重要。 由医学博士约翰·M·霍夫曼和医学博士华莱士·阿克利领导的IDT计划包括来自15个国家的42名成员 系和四所学院。IDT成员包括14名博士、20名博士和8名博士/博士。自.起 2008年12月，会员在同行评审的年度直接成本为720万美元；其中56%来自NCI。这项研究 IDT成员的努力产生了466份出版物，其中17%是方案内出版物，15%是方案间出版物 合作。在2008年期间，IDT方案有36项由调查员发起的试验和176项其他试验 试验：398名受试者被招募参加治疗试验，3479名受试者参加其他试验。

The Imaging, Diagnostics, and Therapeutics Program (IDT) is a new HCI program focused on translating basic discoveries in cancer biology to clinically relevant advanced imaging techniques, diagnostics, drug delivery systems, unique therapeutic approaches, and clinical trials. A major IDT goal is to leverage the strengths of the University of Utah in genetics, pharmaceutics, and imaging along with infrastructure resources to make individualized oncology a reality. An IDT priority has been to increase collaboration with the multidisciplinary disease groups to better understand unmet clinical needs and to bring theoretical and preclinical projects to human applications. IDT is organized along its three thematic scientific strengths: Imaging research efforts include technology development, image-guided therapy, and the new and evolving discipline of molecular imaging. Several Program members are focused on using positron emission tomography imaging with unique radiopharmaceuticals to assess early response to therapeutic intervention. Several members are also involved with image-guided therapy technology development. Diagnostics research efforts include development of novel diagnostic strategies to improve the biologic characterization of cancer for therapeutic treatments and to provide important prognostic information to improve cancer care. Several individuals within the Program are interested in using modern molecular techniques to assess what population of individuals is at risk for developing a certain type of cancer and how particular cancers respond to targeted drug therapies. In addition, prognostic information regarding tumor behavior can be assessed. From these efforts in diagnostic biomarker development, defects in molecular pathways or targets can be identified. Therapeutics research efforts include the development of therapeutic strategies using novel drugs and drug delivery systems. These IDT members perform pre-clinical development, pharmacology, and other required studies to move their discoveries toward clinical applications. Members pursue new drugs and diagnostics through design, compound screening, computational modeling, and chemical synthesis. Members also focus on targeted delivery of anti-cancer agents to tumors and metastases using novel macromolecular drugs and new controlled-release and pro-drug techniques. This thematic group is essential to HCI's clinical trials effort. Led by John M. Hoffman, MD and Wallace Akerley, MD, the IDT Program includes 42 members from 15 departments and four colleges. IDT members include 14 PhDs, 20 MDs, and eight MD/PhDs. As of December 2008, members had $7.2M in peer-reviewed annual direct costs; 56% was from NCI. The research efforts of IDT members have resulted in 466 publications, of which 17% were intra- and 15% were interprogrammatic collaborations. During 2008, the IDT Program had 36 investigator-initiated trials and 176 other trials; 398 subjects were recruited to therapeutic trials and 3,479 subjects to other trials.